Sofinnova books biggest-ever $815M fund with an eye toward up-and-coming ‘global leaders’

Kinam Hong, partner at Sofinnova Partners
“We do not build companies around a single exit route,” Sofinnova partner Kinam Hong, M.D., told Fierce. (Sofinnova)

Life sciences venture capital firm Sofinnova Partners has closed its largest fund ever to the tune of 725 million euros ($815 million), with the cash to be spent on around 15 clinical-stage companies mostly based in Europe.

The fund, called Crossover II, brings the value of Sofinnova’s investment umbrella to more than 5 billion euros (around $5.5 billion), according to a Monday release.

The Crossover II fund has already been busy, according to Sofinnova partner Kinam Hong, M.D., who told Fierce via email that opportunities in immunology, inflammation, oncology, central nervous system disorders, rare disease and cardiometabolic disease are particular areas of focus.

“Above all, we are looking for companies with the potential to become global leaders, not simply assets that can be sold,” Hong said.

Among the first companies in which Crossover II has begun investing are Ireland’s Neurent Medical with a treatment device for chronic rhinitis, Denmark’s Hemab Therapeutics for its bleeding and clotting disorder therapies, and the U.K.’s CellCentric, which is developing an oral oncology platform. About 80% of the fund will be invested in Europe, Hong said.

“All three reflect what we look for: genuine innovation addressing a major unmet medical need; early clinical evidence that the approach works in patients; and the potential to become global leaders,” Hong explained.

The fund’s precursor, Crossover I, backed several life sciences companies that have since been acquired or gone public. They include medical device company LimFlow, which was bought by Inari Medical for $415 million in 2023, drugmaker Calliditas Therapeutics, which was acquired by Asahi Kasei for more than $1 billion in 2024, and rare disease biotech Amolyt Pharma, which AstraZeneca picked up for $800 million that same year.

Biotech Abivax, which received an investment of $14 million from Sofinnova in 2019 as part of Crossover I, made a successful IPO run in 2023 under CEO Marc de Garidel, who Hong credits with being “an important part of that company’s transition.”

A key difference between the two funds is that the sequel will prioritize follow-on investment, Hong said.

“That lets us support companies for longer and maintain meaningful ownership through the milestones that matter most,” Hong said. “We cannot be passive investors. We work closely with management teams, support strategic and operational decisions and help strengthen the team when needed.”

While “exits matter,” acknowledged Hong, the fund is built around more than that one goal.

“We do not build companies around a single exit route,” Hong said. “Biotech companies will sometimes fail because the science does not work. That is part of the risk. They should not fail because they ran out of money or could not execute.”

Sofinnova has bases in Paris, London and Milan. Hong said Europe is home to strong science and promising companies while lacking “large, specialist pools of capital to finance those companies through later-stage development.” The most recent fund is designed to close this gap.

“Pharma needs new products as it faces significant patent expiries through 2030 and beyond,” Hong said. “Much of that innovation will come from biotech, and Europe is well placed.”

The state of biotech funding is one of the hot topics being discussed at Fierce Biotech's high-impact event in London this month. Find out more information and register by clicking on the banner below: